Drugs.com - Clinical Trials

Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

BRAINTREE, Mass., April 23, 2025 /PRNewswire/ – Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology pharmaceutical products, today announced positive topline results from two pivotal US...

May 18, 2025 - 11:38
 0
Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD
BRAINTREE, Mass., April 23, 2025 /PRNewswire/ – Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology pharmaceutical products, today announced positive topline results from two pivotal US...
Read More

Tags:

Previous Article

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of C...

Next Article

Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (uste...

Related Posts

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Merck Announces Positive Topline Results From the First...

Jun 10, 2025  0

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

Click Therapeutics Announces FDA Marketing Authorizatio...

May 12, 2025  0

Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions

Results From Amgen's Phase 2 Obesity Study of Monthly M...

Jun 24, 2025  0